Dendreon Corporation

  DNDN website

DNDN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  433096 of 465582  at  2/28/2012 6:34:39 PM  by

jerzee


Timmerman on Management

 

Dendreon Adds ImClone Vets to New Management Team

Luke Timmerman2/28/12
 

Dendreon CEO John Johnson didn’t waste much time putting together a new management team to help him turn things around at the Seattle-based biotech company (NASDAQ: DNDN).

Johnson, who took over as Dendreon’s CEO on February 1, today installed a trio of new executives. Two of the three are new hires who previously worked with Johnson at New York-based ImClone Systems before that company was acquired for $6.5 billion by Eli Lilly (NYSE: LLY).

With that, here are new names joining the company, according to today’s statement. Johnson pointed out that he’s flattening the company’s management structure, and all three of the new executives will report directly to him.

Joe DePinto, executive vice president, global commercial operations. He will oversee sales and marketing efforts in the U.S., and in Europe, where Dendreon is now seeking regulatory approval for its prostate cancer drug, sipuleucel-T (Provenge). He is new to Dendreon, and most recently was a vice president and product champion at ImClone, the company that developed cetuximab (Erbitux) as a treatment for colorectal cancer.

Robert Poulton, executive vice president, technical operations. Poulton was promoted from global head of quality to this new executive role. He will now oversee global manufacturing, operations, logistics and quality functions, Dendreon said. Poulton previously worked at Wyeth, where he oversaw the supply chain.

Christine Mikail, executive vice president, corporate development, general counsel, and secretary. Mikail was most recently a senior vice president at Savient Pharmaceuticals, where Johnson worked previously, as well as ImClone, where she was vice president, general counsel, and secretary.

Johnson was brought in to help boost the sales of Dendreon’s lone marketed drug, after a 2011 to forget. The company forecasted $350 million to $400 million of sales last year for the drug, and ended up delivering $213 million. The company blamed confusion among doctors about whether they’d get adequate or timely reimbursement for a drug that costs $93,000 per patient. That sales shortfall caused Dendreon to lose more than $3 billion of its market value, and prompted the layoffs of 500 employees last fall. Just yesterday, after the stock had surged for a few weeks, it fell 20 percent again on word that the company expects only “moderate” single-digit sales growth in the first quarter of 2012.

The new executives will have some unique challenges to solve at Dendreon, which is marketing the first treatment of its kind that uses intravenous infusions to “teach” the patient’s immune system to recognize prostate cancer cells as invaders to be destroyed like a virus. The drug has shown an ability to prolong lives by a median time of about four months, with minimal side effects. But the process of delivering the drug is costly. Dendreon’s near-term goal is to reach cash-flow break-even. That goal should be achievable, Dendreon has said, once it gets to $500 million in annual sales, and finds efficiencies in its processes to bring the cost of goods sold down from the current 74 percent to about 50 percent.

Johnson said on Monday’s quarterly conference call that he spent part of his first month on the job meeting with employees at Dendreon’s manufacturing sites in Georgia, southern California, and New Jersey, as well as at headquarters in Seattle. He also spent time meeting with physicians at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium in San Francisco, where clinical trial data was presented on the company’s product.

 http://www.xconomy.com/seattle/2012/02/28/dendreon-adds-imclone-vets-to-new-management-team/


 
     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 29     Views: 643 (updated 24hrs)
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
433099 Re: AF on Management jerzee 5 2/28/2012 6:41:59 PM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help    Advertise
Not a member yet? What are you waiting for? Join Now
Want to contribute? Support InvestorVillage by donating
2003-2013 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...